Abnormal escape from dexamethasone suppression in agoraphobia with panic attacks.
Patients who met DSM-III criteria for agoraphobia with panic attacks underwent dexamethasone suppression tests (DSTs) before, during, and after treatment with alprazolam or placebo. Similarly, outpatients with major depression were given multiple DSTs as they participated in a study of desmethylimipramine efficacy. The likelihood of an abnormal escape from dexamethasone was similar in the two diagnostic groups; nonsuppression was somewhat more likely among patients with primary depression, but comparisons with agoraphobic groups remained statistically insignificant. These results apparently did not reflect misclassification of primary depression patients as agoraphobics since a history of major depression was not related to the likelihood of nonsuppression within that group. Moreover, change in DST results during treatment reflected clinical change among agoraphobics. After a review of relevant followup and family studies, we conclude that panic disorder and primary depression are separate illnesses and that hypothalamic-pituitary-adrenal axis hyperactivity is an epiphenomenon of both.
Coryell
W
W
Noyes
R
R
Clancy
J
J
Crowe
R
R
Chaudhry
D
D
D000328:Adult; D000379:Agoraphobia / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D000525:Alprazolam; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D003866:Depressive Disorder / Q000175:diagnosis / Q000503:physiopathology; D003907:Dexamethasone; D004311:Double-Blind Method; D005239:Fear; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D008297:Male; D010200:Panic; D010698:Phobic Disorders / Q000503:physiopathology*
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; D003907:Dexamethasone; D006854:Hydrocortisone; D000525:Alprazolam